Rana Abdelnabi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2285020/publications.pdf

Version: 2024-02-01

52 papers	4,311 citations	257101 24 h-index	197535 49 g-index
74 all docs	74 docs citations	74 times ranked	6861 citing authors

#	Article	IF	Citations
1	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell, 2021, 184, 2332-2347.e16.	13.5	784
2	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science, 2020, 370, 950-957.	6.0	504
3	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature, 2021, 597, 97-102.	13.7	385
4	Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Research, 2018, 153, 85-94.	1.9	295
5	Broad betacoronavirus neutralization by a stem helixâ€“specific human antibody. Science, 2021, 373, 1109-1116.	6.0	262
6	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2â^'infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26955-26965.	3.3	240
7	Broad sarbecovirus neutralization by a human monoclonal antibody. Nature, 2021, 597, 103-108.	13.7	220
8	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science, 2022, 375, 449-454.	6.0	108
9	The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Antiviral Research, 2022, 198, 105253.	1.9	104
10	Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. EBioMedicine, 2021, 68, 103403.	2.7	102
11	Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. Journal of Infectious Diseases, 2021, 224, 749-753.	1.9	95
12	The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine, 2021, 72, 103595.	2.7	91
13	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nature Communications, 2022, 13, 719.	5.8	86
14	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science, 2022, 377, 735-742.	6.0	85
15	Towards antivirals against chikungunya virus. Antiviral Research, 2015, 121, 59-68.	1.9	84
16	Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase. Journal of Virology, 2017, 91, .	1.5	62
17	An affinity-enhanced, broadly neutralizing heavy chainâ€“only antibody protects against SARS-CoV-2 infection in animal models. Science Translational Medicine, 2021, 13, eabi7826.	5.8	41
18	Chikungunya virus infections: time to act, time to treat. Current Opinion in Virology, 2017, 24, 25-30.	2.6	39

#	Article	IF	Citations
19	A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Reports, 2021, 37, 109814.	2.9	39
20	A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biology, 2019, 17, e3000281.	2.6	36
21	Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication. Bioorganic and Medicinal Chemistry, 2017, 25, 327-337.	1.4	34
22	Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection. Antiviral Research, 2018, 149, 113-117.	1.9	30
23	ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits inÂvivo efficacy in a Syrian Hamster model. Biochemical and Biophysical Research Communications, 2021, 555, 134-139.	1.0	30
24	Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway. Journal of Natural Products, 2016, 79, 680-684.	1.5	28
25	Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site. Science Translational Medicine, 2020, 12, .	5.8	25
26	Antiviral Strategies Against Chikungunya Virus. Methods in Molecular Biology, 2016, 1426, 243-253.	0.4	24
27	Protein kinases C as potential host targets for the inhibition of chikungunya virus replication. Antiviral Research, 2017, 139, 79-87.	1.9	20
28	Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 349-368.	2.9	20
29	A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through TÂcell-mediated immunity. Molecular Therapy, 2022, 30, 2968-2983.	3.7	20
30	Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones. ACS Infectious Diseases, 2018, 4, 605-619.	1.8	18
31	Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death. Journal of Natural Products, 2016, 79, 675-679.	1.5	16
32	Identification of 2-(4-(Phenylsulfonyl)piperazine-1-yl)pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus. ACS Medicinal Chemistry Letters, 2020, 11, 906-912.	1.3	16
33	Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. Thrombosis Research, 2011, 128, 68-76.	0.8	15
34	Understanding the Mechanisms Underlying Host Restriction of Insect-Specific Viruses. Viruses, 2020, 12, 964.	1.5	15
35	Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	15
36	New class of early-stage enterovirus inhibitors with a novel mechanism of action. Antiviral Research, 2017, 147, 67-74.	1.9	14

#	Article	IF	Citations
37	Antiviral drug discovery against arthritogenic alphaviruses: Tools and molecular targets. Biochemical Pharmacology, 2020, 174, 113777.	2.0	14
38	Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors. Microorganisms, 2021, 9, 734.	1.6	13
39	Antiviral Strategies against Arthritogenic Alphaviruses. Microorganisms, 2020, 8, 1365.	1.6	12
40	Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism. Biochemical Pharmacology, 2016, 120, 15-21.	2.0	11
41	Multivalent Tryptophanâ€•and Tyrosineâ€Containing [60]Fullerene Hexaâ€Adducts as Dual HIV and Enterovirus A71 Entry Inhibitors. Chemistry - A European Journal, 2021, 27, 10700-10710.	1.7	9
42	Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains. Vaccine, 2017, 35, 1370-1372.	1.7	8
43	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. Antiviral Research, 2022, 202, 105311.	1.9	8
44	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. IScience, 2022, 25, 104705.	1.9	8
45	Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10027-10046.	2.9	7
46	Perturbation of Alphavirus and Flavivirus Infectivity by Components of the Bacterial Cell Wall. Journal of Virology, 2022, 96, jvi0006022.	1.5	3
47	Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model. Microorganisms, 2022, 10, 633.	1.6	3
48	In silico development of a novel putative inhibitor of the 3C protease of Coxsackievirus B3 with a benzene sulfonamide skeleton. Journal of Pharmaceutical Chemistry, 2017, 4, 25-34.	0.2	1
49	Organotropic dendrons with high potency as HIV-1, HIV-2 and EV-A71 cell entry inhibitors. European Journal of Medicinal Chemistry, 2022, 237, 114414.	2.6	1
50	Chikungunya virus resistant to the antiviral favipiravir is severely attenuated in mosquitoes. Access Microbiology, 2019, 1, .	0.2	0
51	A novel class of small molecule inhibitors targeting the chikungunya virus capping machinery with a high barrier to resistance. Access Microbiology, 2019, 1, .	0.2	0
52	Pan-antivirals to combat re-emerging alphaviruses. Access Microbiology, 2019, 1, .	0.2	0